eli lilly tirzepatide fda approval OKs Zepbound for weight-loss Diabetes drug resolves sleep apnea

Interpretation of findings Weight loss improves cardiovascular risk factorsa recent trial showed that continuous use of semaglutide over four years reduced major cardiovascular disease events in individuals with existing cardiovascular disease.9 The benefits of weight loss on diabetes and other cardiovascular disease risk markers were, however, attenuated by weight regain.10 Based on projections of observed trends, we estimated that people who stop taking WMMs will regain weight at a rate of 0.4 kg/month, returning to baseline weight by 1.7 years and to no difference from control after 1.4 years

Month 58 Target Dose Steady State You've reached (or are approaching) your target dose

(including L

Transdermal HRT patches are particularly compatible with semaglutide because they bypass hepatic metabolism entirely

Who Is Eligible for the Zepbound Discount